| Literature DB >> 29120753 |
Eldad Zacksenhaus1, Mariusz Shrestha2, Jeff C Liu3, Ioulia Vorobieva2, Philip E D Chung2, YoungJun Ju3, Uri Nir4, Zhe Jiang3.
Abstract
A switch from catabolic to anabolic metabolism, a major hallmark of cancer, enables rapid cell duplication, and is driven by multiple oncogenic alterations, including PIK3CA mutation, MYC amplification, and TP53 loss. However, tumor growth requires active mitochondrial function and oxidative phosphorylation (OXPHOS). Recently, loss of the retinoblastoma (RB1) tumor suppressor in breast cancer was shown to induce mitochondrial protein translation (MPT) and OXPHOS. Here, we discuss how increased OXPHOS can enhance anabolic metabolism and cell proliferation, as well as cancer stemness and metastasis. Mitochondrial STAT3, FER/FER-T, and CHCHD2 are also implicated in OXPHOS. We propose that RB1 loss represents a prototypic oncogenic alteration that promotes OXPHOS, that aggressive tumors acquire lethal combinations of oncogenes and tumor suppressors that stimulate anabolism versus OXPHOS, and that targeting both metabolic pathways would be therapeutic. CrownEntities:
Keywords: anabolic metabolism; breast cancer; cancer stem cell; glycolysis; metastasis; mitochondrial protein translation; oxidative phosphorylation; tumor suppressor RB1
Mesh:
Substances:
Year: 2017 PMID: 29120753 DOI: 10.1016/j.trecan.2017.09.002
Source DB: PubMed Journal: Trends Cancer ISSN: 2405-8025